Genmab — April 2013
-
Jeg tror på off-label salg i CLL 2nd line og vedligehold, hvis ellers Frontline data er gode.
-
Hvis godkendt i 1st line og 3rd line kan det bruges på hele paletten.
-
36 mill rekord
-
ja 53% qoq
-
de må nok ud og opjusterer ved næste q hvis det fortsætter sådan her
-
-
-
Zalutumumab ADC?
-
vrøvl. Zalutumumab in combination with radiotherapy and a radiosensitizing agent.
-
Hvorfor mon Dr Overgaard har brug for sådan et patent kort før Dahanca resultater?
-
Z: hate
-
Hexabody kan vel ikke katagoriseres som radiosensitizing agent vel?
-
indsent i december .jvorfor gør man det i et stof man har opgivet?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind